Scaling up for unprecedented global vaccine manufacturing

1 Jun 2020

Vaxxas announces Merck (known as MSD outside the US and Canada) milestone and Harro Höfliger manufacturing alliance.

Vaxxas has announced two developments relating to its novel high-density microarray patch (HD-MAP), which uses an ultra-high density array of projections — invisible to the naked human eye — applied to the skin to rapidly deliver any vaccine to the abundant immune cells immediately below the skin surface.

Scaling up for unprecedented global vaccine manufacturing

Vaxxas HD-MAP could be a game-changing technology for vaccine delivery in pandemic situations such as COVID-19 or influenza because it makes it possible to vaccinate up to six times more people using the same amount of vaccine — each patch uses a percentage of the vaccine dose needed by conventional delivery approaches.

Merck has exercised its option to utilize Vaxxas’ proprietary HD-MAP) platform for an unidentified vaccine candidate. The company also retains an option to license the HD-MAP technology for two additional vaccines.

Vaxxas will receive $12 million (A$18 million) in a combination of equity funding and option fees associated with the agreement. In addition, the company is eligible to receive future option, development, and commercial milestone payments.

In a separate agreement, Vaxxas and Harro Höfliger, a leader in sterile processing and scale-up of new pharmaceutical products, technologies and devices, will develop the world’s first high-throughput aseptic line for vaccine-HD-MAP production.

Single, aseptic-based lines will have a targeted throughput of up to 5 million vaccine products/week. Initial efforts are focused on a pilot line operating in 2021 to be used to support late-stage clinical studies.

"A major challenge in commercializing microarray patches — like Vaxxas’ HD-MAP — for vaccination is the ability to manufacture at industrially relevant scale while meeting stringent sterility and quality standards. Our novel device design along with our innovative vaccine coating and quality verification technologies are an excellent fit for integration with Harro Höfliger’s aseptic process automation platforms. Adopting a modular approach, it will be possible to achieve an output of tens-of-millions of vaccine-HD-MAP products per week,” said David L. Hoey, President and CEO of Vaxxas.

For routine infectious disease more than 750 million vaccinations are administered worldwide each year by needle/syringe. In the case of pandemic response, billions of vaccinations may need to occur in a variety of settings. Vaxxas’ HD-MAP has the potential to create new needle-free vaccine products with enhanced immune response and designed for improved safety, storage, and distribution logistics to extend the reach of vaccines and improve vaccination efficiency and effectiveness.

Read More

Related news

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

7 Jul 2020

The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.

Read more 
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

7 Jul 2020

The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.

Read more 
Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids

6 Jul 2020

The transaction will more than double Croda’s R&D capability in drug delivery.

Read more 
Rentschler Biopharma and Vetter team up to simplify processes

Rentschler Biopharma and Vetter team up to simplify processes

6 Jul 2020

Companies agree that the key to tackling drug development complexity is collaboration.

Read more 
Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility

Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility

6 Jul 2020

An investment of $3.6 million will cover the installation of a new production line to keep pace with continued growth in commercial-scale API manufacturing.

Read more 
iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
Catalent expands beauty and plant-based consumer health softgel capabilities

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more